Lys338
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.7
Powered by Cell Signaling Technology
Home > Acetylation Site Page: > Lys338  -  HOXA10 (human)

Site Information
LTAKsGRkkRCPyTk   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 31094516

In vivo Characterization
Methods used to characterize site in vivo:
modification-specific antibody ( 1 ) , mutation of modification site ( 1 ) , western blotting ( 1 )
Disease tissue studied:
endometrial cancer ( 1 ) , endometrial adenocarcinoma ( 1 ) , urethral cancer ( 1 )
Relevant cell line - cell type - tissue:
BeWo ( 1 ) , HEK293T (epithelial) ( 1 ) , Ishikawa (endometrial) ( 1 )

Upstream Regulation
Treatments:
diethylstilbestrol ( 1 ) , H-89 ( 1 ) , LY294002 ( 1 ) , progesterone ( 1 ) , SB203580 ( 1 ) , siRNA ( 1 ) , SP600125 ( 1 ) , U0126 ( 1 )

Downstream Regulation
Effects of modification on HOXA10:
protein degradation ( 1 )
Effects of modification on biological processes:
cell adhesion, inhibited ( 1 ) , transcription, inhibited ( 1 )

References 

1

Zhu LH, et al. (2013) PCAF impairs endometrial receptivity and embryo implantation by down-regulating β3-integrin expression via HOXA10 acetylation. J Clin Endocrinol Metab 98, 4417-28
24037888   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.